ABO血型与卵巢肿瘤发生危险度及卵巢恶性肿瘤化疗敏感性关系

Relationship of ABO blood group with the risk of ovarian tumor and chemotherapy sensitivity for malignant ovarian tumor

目的 探讨卵巢肿瘤患者ABO血型分布特点以及卵巢恶性肿瘤化疗效果与ABO血型的关系。方法 卵巢肿瘤患者751例,其中卵巢恶性肿瘤275例为恶性肿瘤组,卵巢交界性肿瘤76例为交界性肿瘤组,卵巢良性肿瘤400例为良性肿瘤组;同期健康体检者300例为对照组。采用相对危险度（odds ratio,OR）分析ABO血型与卵巢肿瘤发生、卵巢恶性肿瘤化疗敏感性的关系。结果 卵巢恶性肿瘤组与对照组血型构成比比较差异有统计学意义（P〈0.05）,卵巢交界性肿瘤组、良性肿瘤组与对照组比较差异无统计学意义（P〉0.05）;B型血者为卵巢恶性肿瘤高风险人群（OR=1.118,95%CI：1.008~1.239,χ~2=4.572,P=0.032）,O型血者为卵巢恶性肿瘤（OR=0.867,95%CI：0.775~0.969,χ~2=6.278,P=0.012）、卵巢交界性肿瘤（OR=0.830,95%CI：0.713~0.966,χ~2=4.552,P=0.033）低风险人群;卵巢良性肿瘤组与对照组各血型发病风险比较差异无统计学意义（P〉0.05）;卵巢恶性肿瘤组O型血患者化疗有效率优于非O型血患者（P〈0.05）,临床控制率在ABO血型之间差异无统计学意义（P〉0.05）。结论 B型血者为卵巢恶性肿瘤高风险人群,O型血者为卵巢恶性肿瘤、卵巢交界性肿瘤低风险人群,O型血卵巢恶性肿瘤患者化疗效果优于其他血型患者。

Objective To explore the distribution features of ABO blood group and the relationship of ABO blood group with the chemotherapy results of malignant ovarian tumor. Methods A total of 751 patients with ovarian tumors were divided into malignant ovarian tumor group （n=275）, borderline ovarian tumor group （n=76） and benign tumor group （n=400）. And another 300 healthy volunteers were as controls （control group）. Odds ratio （OR） value was adopted to analyze the relationships of ABO blood group with the development of ovarian tumor and the chemotherapy sensitivity for malignant ovarian tumor. Results There was a significant difference in the constituent ratio of ABO blood group between malignant ovarian tumor group and control group （P〈0.05）, and there were no significant differences among borderline ovarian tumor group, benign tumor group and control group （P〈0, 05）. The patients with B blood group had a high risk of ovarian cancer （OR=1. 118, 95%CI： 1.008 to 1.239, χ2 =4. 572, P=0.032）, and the patients with O blood group had a low risk of ovarian cancer （OR=0. 867, 95%CI： 0. 775 to 0. 969, χ^2 =6. 278, P=0. 012） and borderline ovarian tumors （OR=0.830, 95%CI： 0.713 to 0.966, χ^2=4.552, P=0.033）. The OR values of ABO blood group showed no significant differences between benign ovarian tumor group and control group （P〉0.05）. The chemotherapy response rate with O blood group was significantly better than that in patients with the other blood groups in malignant ovarian tumor group （P〈0.05）. There was no significant difference in the clinical control rate among ABO blood groups （P〉 0.05）. Conclusion The patients with B blood group have a higher risk of malignant ovarian tumor, and the patients with O blood group have a lower risk of malignant and borderline ovarian tumor. Chemotherapy effect in malignant ovarian tumor patients with O blood group is significantly better than that in patients with other blood groups.